To confirm p53 activation by MDM2 inhibition we determined the expression levels of the tumor suppressor protein p53, of the activated acetylated p53 protein and of the p53 target gene CDKN1A in AML cells treated for 24 h with single compounds and with combined treatment. This evidence concerns the gene CDKN1A and acute myeloid leukemia.